Parkinson's Disease Flashcards
Clinical signs of PD (TRAP pneumonic)
- Tremor at rest
- Rigidity
- Akinesia or bradykinesia
- Postural/gait instability
Neurotransmitters involved in PD
- Dopamine*** (deficiency)
- NE
- ACh
- Glutamate
- Seratonin
“1st Line PD drugs”
- Levodopa plus carbidopa +/- entacopone
- Dopamine agonists
“2nd Line PD drugs”
- Anticholinergics
- Selective MOA B inhibitors
- NMDA antagonists
Levodopa Products
- Carbidopa/Levodopa
- Carbidopa/Levodopa/Entacapone
Levodopa MOA
Travels to BBB where it gets decarboxylated to dopamine
Carbidopa MOA
- blocks conversion of levo to dopamine before BBB
- *Minimize N/V, orthostatic hypoTN ass with levo
Entacapone
-Prolong action of levo by inhibiting O-methylation
Anticholinergics
Trihexyphenidyl and Benztropine
Anticholinergics MOA
Dopamine depletion in PD = state of cholinergic sensitivity, cholinergic drugs excite and anticholinergic drugs improve parkinsonian symptoms
Clinical indications of anticholinergics
Early: mild tremor
Later: enhance the effects of levodopa, may help with drooling but ADRs frequently limit widespread application
Anticholinergics pearl
Both can be used to treat drug-induced EPS
NMDA Antagonists
Amantadine
NMDA MOA
Increase dopamine release, decrease dopamine reuptake, stimulate dopamine receptors; interferes with excessive glutamate neurotransmission
Clinical indications of NMDA Antagonists
Early: limited data
Later: *adjunct tx, usually in pts with levodopa-induced dyskinesia)
Less effective after 1 year of use